LT2726600T - Žinduolių ląstelių kultūra - Google Patents

Žinduolių ląstelių kultūra

Info

Publication number
LT2726600T
LT2726600T LTEP12738674.6T LT12738674T LT2726600T LT 2726600 T LT2726600 T LT 2726600T LT 12738674 T LT12738674 T LT 12738674T LT 2726600 T LT2726600 T LT 2726600T
Authority
LT
Lithuania
Prior art keywords
cell culture
mammalian cell
mammalian
culture
cell
Prior art date
Application number
LTEP12738674.6T
Other languages
English (en)
Inventor
Brian D. Follstad
Rebecca E. Mccoy
Arvia E. Morris
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2726600(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of LT2726600T publication Critical patent/LT2726600T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP12738674.6T 2011-07-01 2012-06-29 Žinduolių ląstelių kultūra LT2726600T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503737P 2011-07-01 2011-07-01
PCT/US2012/045070 WO2013006479A2 (en) 2011-07-01 2012-06-29 Mammalian cell culture

Publications (1)

Publication Number Publication Date
LT2726600T true LT2726600T (lt) 2017-05-25

Family

ID=46579326

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14187232.5T LT2837680T (lt) 2011-07-01 2012-06-29 Žinduolių ląstelių kultūra
LTEP12738674.6T LT2726600T (lt) 2011-07-01 2012-06-29 Žinduolių ląstelių kultūra

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP14187232.5T LT2837680T (lt) 2011-07-01 2012-06-29 Žinduolių ląstelių kultūra

Country Status (24)

Country Link
US (7) US11292829B2 (lt)
EP (2) EP2837680B1 (lt)
JP (1) JP5897708B2 (lt)
KR (7) KR102108663B1 (lt)
CN (2) CN107988166B (lt)
AU (5) AU2012279230B2 (lt)
BR (2) BR112013033730B1 (lt)
CA (2) CA2838695C (lt)
CL (2) CL2013003792A1 (lt)
CY (2) CY1118863T1 (lt)
DK (2) DK2726600T3 (lt)
EA (1) EA039023B1 (lt)
ES (2) ES2788132T3 (lt)
HK (2) HK1197081A1 (lt)
HU (2) HUE033279T2 (lt)
IL (5) IL288509B2 (lt)
LT (2) LT2837680T (lt)
MX (1) MX351974B (lt)
PL (2) PL2837680T3 (lt)
PT (2) PT2837680T (lt)
SG (1) SG10201702537RA (lt)
SI (2) SI2837680T1 (lt)
WO (1) WO2013006479A2 (lt)
ZA (1) ZA201309372B (lt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
MX2009002748A (es) 2006-09-13 2009-03-26 Abbott Lab Mejoras de cultivos celulares.
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2838695C (en) * 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
KR20140083037A (ko) 2011-10-18 2014-07-03 코히러스 바이오사이언시즈, 인코포레이티드 아미노산으로 안정화된 에타너셉트 제형
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EA029193B1 (ru) 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PE20150996A1 (es) 2012-09-11 2015-08-01 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
WO2014109858A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
KR20150133833A (ko) * 2013-03-26 2015-11-30 코히러스 바이오사이언시즈, 인코포레이티드 단백질 생산 방법
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
CA2929077C (en) * 2013-10-31 2024-05-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
WO2015105609A1 (en) 2014-01-13 2015-07-16 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
BR112016017630A2 (pt) 2014-01-30 2017-08-08 Coherus Biosciences Inc Meios de perfusão
HUE042277T2 (hu) * 2014-06-04 2019-06-28 Amgen Inc Eljárások fehérjék begyûjtésére emlõssejttenyészetekbõl
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TWI707949B (zh) * 2014-06-09 2020-10-21 美商健臻公司 種子罐培養法（ｓｅｅｄ ｔｒａｉｎ ｐｒｏｃｅｓｓｅｓ）及其用途
JP6530171B2 (ja) * 2014-09-09 2019-06-12 旭化成メディカル株式会社 培養産生物の回収方法
PL3227454T3 (pl) 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105385731B (zh) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 一种表达重组八因子的灌注培养方法
MX2018008448A (es) * 2016-01-06 2019-05-30 Oncobiologics Inc Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
EP3423588A1 (en) * 2016-03-02 2019-01-09 Lonza Ltd Improved fermentation process
WO2018178063A1 (en) * 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Perfusion medium
AU2018241849B2 (en) 2017-03-31 2023-06-22 Boehringer Ingelheim International Gmbh Perfusion medium
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
KR20200068697A (ko) 2017-10-06 2020-06-15 론자 리미티드 라만 분광법을 사용하는 세포 배양의 자동 제어
CA3075679A1 (en) 2017-10-16 2019-04-25 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
SG11202005272SA (en) * 2017-12-08 2020-07-29 Juno Therapeutics Inc Process for producing a composition of engineered t cells
EP3818078B1 (en) * 2018-07-03 2024-02-28 Bristol-Myers Squibb Company Methods of producing recombinant proteins
JP2022516516A (ja) * 2018-12-31 2022-02-28 レプリゲン・コーポレーション 疎水性中空繊維による哺乳類細胞培養物の灌流および浄化用フィルター
AU2020352651A1 (en) 2019-09-27 2022-03-24 Boehringer Ingelheim International Gmbh Concentrated perfusion medium
WO2022036275A2 (en) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Manufacturing process for protein
JP2023542820A (ja) * 2020-08-31 2023-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
CN114574430A (zh) * 2022-03-22 2022-06-03 成都博宠生物科技有限公司 一种Expi293F细胞培养方法
CN115287251A (zh) * 2022-08-25 2022-11-04 无锡药明生物技术股份有限公司 间歇性灌流联合分批流加培养
WO2024054414A1 (en) 2022-09-06 2024-03-14 Amgen Inc. Lean perfusion cell culture methods
WO2024059235A2 (en) 2022-09-16 2024-03-21 Amgen Inc. A method for harvesting products from perfusion cultures
CN116790483B (zh) * 2023-08-22 2023-10-20 苏州依科赛生物科技股份有限公司 一种cho细胞无血清培养基及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4499064A (en) 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0417563T3 (da) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US7037721B1 (en) * 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
ES2198414T3 (es) 1992-10-23 2004-02-01 Immunex Corporation Procedimientos para preparar proteinas oligomericas solubles.
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US20030036505A1 (en) 2000-09-25 2003-02-20 Human Genome Sciences, Inc. Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon
EP1404813A4 (en) 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP2005521401A (ja) 2002-03-27 2005-07-21 イミュネックス・コーポレーション ポリペプチド産生を増加させる方法
US8206981B2 (en) * 2004-03-05 2012-06-26 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
CN1332024C (zh) * 2004-06-09 2007-08-15 中国科学院大连化学物理研究所 一种海绵细胞的微载体三维培养方法
DE602005027508D1 (de) 2004-07-07 2011-05-26 Coloplast As Katheter enthaltend ESTANE 58212
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
ES2370417T3 (es) * 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
EP2634250B1 (en) 2006-07-14 2017-04-05 Patheon Holdings I B.V. Improved process for the culturing of cells
WO2008024769A2 (en) * 2006-08-21 2008-02-28 Raven Biotechnologies, Inc. Intensified perfusion production method
KR101523782B1 (ko) 2006-11-08 2015-05-28 와이어쓰 엘엘씨 세포 배양을 위한 합리적으로 설계된 배지
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
EP2188371B1 (en) 2007-08-09 2017-12-20 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CA2734922C (en) 2008-09-15 2020-01-14 Laetitia Malphettes Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
IN2012DN00801A (lt) 2009-07-31 2015-06-26 Baxter Int
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
KR20200111282A (ko) 2009-08-11 2020-09-28 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
EP3255153A1 (en) 2009-11-17 2017-12-13 E. R. Squibb & Sons, L.L.C. Methods for enhanced protein production
WO2011065940A1 (en) 2009-11-24 2011-06-03 Biogen Idec Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
DK2635604T3 (en) * 2010-11-01 2017-02-27 Symphogen As PAN-HER-ANTIBODY COMPOSITION
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
CA2838695C (en) * 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
CA2929077C (en) 2013-10-31 2024-05-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
RU2761633C2 (ru) * 2015-11-17 2021-12-13 Пфайзер Инк. Среды и способы ферментации для производства полисахаридов в бактериальной клеточной культуре

Also Published As

Publication number Publication date
KR20140031375A (ko) 2014-03-12
DK2726600T3 (en) 2017-05-15
KR102358951B1 (ko) 2022-02-08
US20210061888A1 (en) 2021-03-04
PT2726600T (pt) 2017-04-24
CN107988166B (zh) 2022-03-15
CN103827292B (zh) 2018-01-26
IL297998A (en) 2023-01-01
US11673941B2 (en) 2023-06-13
IL288509B (en) 2022-12-01
AU2018203972A1 (en) 2018-06-21
EP2837680B1 (en) 2020-02-26
PT2837680T (pt) 2020-04-17
AU2020281075A1 (en) 2021-01-07
PL2726600T3 (pl) 2017-08-31
JP2014520534A (ja) 2014-08-25
KR20240005106A (ko) 2024-01-11
KR20180050433A (ko) 2018-05-14
CA2838695C (en) 2017-02-14
CN103827292A (zh) 2014-05-28
CL2016001190A1 (es) 2017-06-09
BR112013033730A2 (pt) 2017-01-31
ES2788132T3 (es) 2020-10-20
US20220185869A1 (en) 2022-06-16
KR101662412B1 (ko) 2016-10-04
HK1197081A1 (en) 2015-01-02
IL288509A (en) 2022-01-01
JP5897708B2 (ja) 2016-03-30
KR20220021008A (ko) 2022-02-21
KR102558247B1 (ko) 2023-07-24
IL278430B (en) 2022-01-01
AU2018203972B2 (en) 2020-09-17
US20230117598A1 (en) 2023-04-20
EP2726600B1 (en) 2017-02-15
HUE033279T2 (en) 2017-11-28
HK1206057A1 (en) 2015-12-31
ZA201309372B (en) 2014-08-27
CN107988166A (zh) 2018-05-04
US11685772B2 (en) 2023-06-27
IL310968A (en) 2024-04-01
US11292829B2 (en) 2022-04-05
CY1118863T1 (el) 2018-01-10
US20230227535A1 (en) 2023-07-20
KR20200051046A (ko) 2020-05-12
SG10201702537RA (en) 2017-04-27
US11634476B2 (en) 2023-04-25
BR112013033730B1 (pt) 2022-01-25
KR101857380B1 (ko) 2018-05-11
AU2023201127A1 (en) 2023-03-30
IL229803B (en) 2020-11-30
KR20160075814A (ko) 2016-06-29
MX2013014937A (es) 2014-04-16
KR102108663B1 (ko) 2020-05-07
MX351974B (es) 2017-11-06
AU2012279230B2 (en) 2016-08-18
US11827692B2 (en) 2023-11-28
EP2726600A2 (en) 2014-05-07
CL2013003792A1 (es) 2014-07-25
SI2726600T1 (sl) 2017-07-31
PL2837680T3 (pl) 2020-08-10
EA201391826A1 (ru) 2014-04-30
DK2837680T3 (da) 2020-04-27
IL297998B1 (en) 2024-03-01
US20230129523A1 (en) 2023-04-27
WO2013006479A2 (en) 2013-01-10
KR20230114317A (ko) 2023-08-01
EP2837680A1 (en) 2015-02-18
EA039023B1 (ru) 2021-11-23
IL288509B2 (en) 2023-04-01
ES2625045T3 (es) 2017-07-18
US20200407427A1 (en) 2020-12-31
AU2020281075B2 (en) 2022-12-22
SI2837680T1 (sl) 2020-07-31
CY1123146T1 (el) 2021-12-31
AU2012279230A1 (en) 2014-01-09
AU2016244255A1 (en) 2016-10-27
HUE049119T2 (hu) 2020-09-28
CA2952347A1 (en) 2013-01-10
CA2838695A1 (en) 2013-01-10
LT2837680T (lt) 2020-07-10
US20140255993A1 (en) 2014-09-11
BR122021007265B1 (pt) 2022-02-22
WO2013006479A3 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
IL288509A (en) Mammalian cell culture
SG10201601434RA (en) Cell Culture System
EP2729561A4 (en) CELL CULTURE METHOD
EP2759592A4 (en) ADHÄSIONSZELLKULTURVERFAHREN
HK1183057A1 (en) Cell culture insert
IL226971B (en) Cell culture medium
SG11201503579RA (en) Cell culture med
EP2772530A4 (en) CELL CULTURE ASSAY
EP3144319B8 (en) Cell culture composition comprising laminin-521
SG10201700670WA (en) Cell culture
EP2796537A4 (en) CELL CULTURE SUPPORT
HUE058968T2 (hu) Sejtkultúra tenyésztésére szolgáló eszköz
GB201211873D0 (en) Cell culture
GB201114752D0 (en) Cell staining process
GB201007863D0 (en) Bioreactor for cell culture
GB201120446D0 (en) Mammalian cell transformation method
GB201007855D0 (en) Bioreactor for the culture of cells
GB201016327D0 (en) Mammalian cell preservation methods
AU2011903899A0 (en) Cell culture & expansion
GB201000999D0 (en) Mammalian cell preservation methods
PL393251A1 (pl) Mikroukład do hodowli komórkowej
GB201115343D0 (en) Mammalian Haploid embryonic stem cells
GB201110577D0 (en) Culturing microorganisms
GB201020075D0 (en) Mammalian cell transformation method